Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Acute symptomatic uni- or bilateral Deep Vein Thrombosis (DVT) of the leg involving proximal veins, and/or Pulmonary Embolism (PE)~* Male or female, being 18 years of age or older~* Written informed consent for study participation~Exclusion criteria:~* Persistent symptoms of VTE~* PE requiring urgent intervention~* Use of vena cava filter~* Contraindications to anticoagulant therapy~* Allergy to study medications~* Elevated Aspartate-aminotransferase (AST) or Alanine-aminotransferase (ALT) \> 3x Upper Limit of Normal (ULN) or known liver disease expected to have an impact on survival~* Severe renal impairment~* Patients considered unsuitable for inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dabigatran etexilate (150mg bid) (Type: EXPERIMENTAL): Patients will receive 1 capsule containing 150 mg dabigatran etexilate/matching placebo twice daily
- Warfarin (INR 2.0-3.0) (Type: ACTIVE_COMPARATOR): Patients will receive tablets PRN warfarin/matching placebo to maintain a target INR of 2.0-3.0

Based on this trial design, predict the completion outcome and termination type (if applicable).